{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:31Z","timestamp":1794242971501,"version":"4.9.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 53-year-old man who has stage 4 non-small cell lung carcinoma and treated with Dabrafenib-Trametinib combination chemotherapy; presented with decreased bilateral visual acuity. We checked out slit lamp examination, fundoscopy, optical coherence tomography and fundus fluorescein angiography. In slit lamp biomicroscopy; bilateral posterior synechiae, granulomatous keratic precipitates and\u2009+\u20094 cells in the anterior chamber were detected. Cystoid macular edema and subretinal fluid accumulation were revealed in optical coherence tomography. Dabrafenib and Trametinib treatments were discontinued and systemic methylprednisolone, topical corticosteroid and topical cyclopentolate were started. His best corrected visual acuity was increased from counting fingers from 2\u00a0m to 0,9 bilaterally and cystoid macular edema and serous retinal detachment were completely regressed as a result of systemic and topical corticosteroid treatment.<\/jats:p>","DOI":"10.1186\/s12348-023-00339-0","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T17:02:50Z","timestamp":1681318970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ocular side effects of Trametinib and Dabrafenib: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Bilge","family":"Tar\u0131m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"9","key":"339_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 10(9):1240\u201342","journal-title":"J Thorac Oncol."},{"key":"339_CR2","doi-asserted-by":"publisher","first-page":"244e285","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244e285.","journal-title":"J Thorac Oncol"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"82e94","DOI":"10.1016\/j.ctrv.2018.04.006","volume":"66","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, Facchinetti F, Rossi G et al (2018) BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev 66:82e94.","journal-title":"Cancer Treat Rev"},{"key":"339_CR4","first-page":"984e993","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984e993.","journal-title":"Lancet Oncol"},{"key":"339_CR5","doi-asserted-by":"publisher","first-page":"855e867","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855e867.","journal-title":"Cell"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"209e221","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn SJ, Milagre C, Whittaker S et al (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209e221.","journal-title":"Cell"},{"issue":"7","key":"339_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/IAE.0000000000000242","volume":"34","author":"CY Liu","year":"2014","unstructured":"Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, Marmor MF, Abramson DH (2014) Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 34(7):1261\u20131280.","journal-title":"Retina"},{"issue":"9","key":"339_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.oftal.2018.01.008","volume":"93","author":"T Rueda-Rueda","year":"2018","unstructured":"Rueda-Rueda T, S\u00e1nchez-Vicente JL, Moruno-Rodr\u00edguez A, Molina-Socola FE, Mart\u00ednez-Borrego AC, L\u00f3pez-Herrero F (2018) Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol (Engl Ed). 93(9):458\u2013462 English, Spanish.","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)."},{"issue":"2","key":"339_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1188\/16.ONF.235-243","volume":"43","author":"ME Davis","year":"2016","unstructured":"Davis ME (2016) Ocular Toxicity of Tyrosine Kinase Inhibitors. Oncol Nurs Forum 43(2):235\u2013243.","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"339_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3322\/caac.21184","volume":"63","author":"GK Dy","year":"2013","unstructured":"Dy GK, Adjei AA (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63(4):249\u2013279.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"339_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","volume":"25","author":"U Urner-Bloch","year":"2014","unstructured":"Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, Moutouh-de Parseval L, Dummer R, Goldinger SM (2014) Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 25(7):1437\u20131441.","journal-title":"Ann Oncol"},{"issue":"3","key":"339_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000357060","volume":"4","author":"L Joshi","year":"2013","unstructured":"Joshi L, Karydis A, Gemenetzi M, Shao EH, Taylor SR (2013) Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol. 4(3):279\u201382","journal-title":"Case Rep Ophthalmol."},{"issue":"1","key":"339_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","volume":"17","author":"S Sarny","year":"2017","unstructured":"Sarny S, Neumayer M, Kofler J, El-Shabrawi Y (2017) Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmol 17(1):146.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"339_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/meajo.MEAJO_252_16","volume":"24","author":"PD Majumder","year":"2017","unstructured":"Majumder PD, Ghosh A, Biswas J (2017) Infectious uveitis: An enigma. Middle East Afr J Ophthalmol. 24(1):2\u201310.","journal-title":"Middle East Afr J Ophthalmol."},{"issue":"1","key":"339_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","volume":"62","author":"GA O'Keefe","year":"2017","unstructured":"O\u2019Keefe GA, Rao NA (2017) Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 62(1):1\u201325.","journal-title":"Surv Ophthalmol."},{"issue":"10","key":"339_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1051\/medsci\/2020160","volume":"36","author":"F Hoogewoud","year":"2020","unstructured":"Hoogewoud F, Kowalczuk L, Bousquet E, Br\u00e9zin A, Touchard E, Buggage R, Bordet T, Behar-Cohen F (2020) Les anti-TNF-\u03b1 pour le traitement des uv\u00e9ites non infectieuses [Anti-TNF-\u03b1 in the treatment of non-infectious uveitis]. Med Sci (Paris). 36(10):893\u2013899 French.","journal-title":"Med Sci (Paris)."}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00339-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:52:31Z","timestamp":1729227151000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00339-0","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"9 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the principles of the Declaration of Helsinki. The study was approved by the review board of the Ankara City Hospital. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publication (including images, personal and clinical details of the participant) was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}